Eliane van Doorn has joined event organisers CMP Information (CMPi) as group director for its expanding Pharma Ingredients Group - best known for its family of CPhI pharma services events. Reporting to Simon Foster, CMPi's md of international exhibitions, van Doorn will direct the growth and development of the CPhI, ICSE, and P-MEC event brands - heading a strong international management, marketing, operations and sales team based in Maarssen, near Amsterdam.
Amarin Corporation has appointed Declan Doogan to the newly-created position of president, research & development. Most recently, Doogan was senior vice president and head of worldwide development at Pfizer global r&d, and previously held a number of senior positions in Pfizer in the US and the UK. Doogan led the Zoloft clinical development program.
Riccardo Trecroce has been confirmed as ceo of Patheon for an indefinite period. Trecroce was initially appointed as ceo for an interim period in September 2006.
Following the recent appointment of Tom Luken as president, Romaco has also added Gary Kedgley (pictured) to its senior management team as vice-president, sales and marketing. Kedgley's brief is to support Luken in directing and growing Romaco's worldwide business, including production centres in Germany, Italy and Switzerland and all sales channels. He is based at Romaco's European hq in Karlsruhe, Germany. Kedgley's most recent role was that of vice-president, global project sales and management for Invensys APV, with responsibility for 300 staff and circa £ 200 million in annual revenues.
UK-based Cellexus Biosystems has appointed Julie Bick as its chief scientific officer. Bick has the world-wide responsibility for leading the company's research and customer support programmes and will be based in the US. Bick brings a high level of experience in protein biochemistry to the role, ranging from the development of expression and purification methods, analysis of membrane transport systems and biosynthetic metabolic pathways of yeast, plants and mammals, and studies of protein kinases and signal transduction cascades within biological systems. Prior to joining Cellexus, Bick was a senior scientist at Sanofi-Aventis.
Biotech firm Codexis has added two new positions. Joseph Sarret has been named vice president, corporate development and Douglas Sheehy has been appointed vice president, general counsel and corporate secretary. Both will report to president and ceo Alan Shaw. Sarret was previously director of business development and corporate counsel for Codexis. Sheehy joins Codexis from CV Therapeutics, a publicly-traded biopharmaceutical company,